Omkar Pharmachem Stock Price Today (NSE: 532167)
Fundamental Score
Omkar Pharmachem Share Price Live NSE/BSE & Institutional Fundamental Analysis
Omkar Pharmachem share price today is ₹26.83, up +0.00% on NSE/BSE as of 30 September 2025. Omkar Pharmachem (532167) is a Small-cap company in the Chemicals & Petrochemicals sector with a market capitalisation of ₹27.06 (Cr). The 52-week high for 532167 share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 150.33x, 532167 is currently trading above its industry average P/E of 22.17x. The company has a Return on Equity (ROE) of 2.14% and a debt-to-equity ratio of 0.01.
Omkar Pharmachem Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Omkar Pharmachem Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Research report currently being updated.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Omkar Pharmachem Fundamental Analysis & Valuation Benchmarking
Educational evaluation of 532167 across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Strong Operating Margins (49.79%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Consistent Growth Track Record (60.95% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (22.59% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (22.59% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.01)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (14.50x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (2.14%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (3.04%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 150.33x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-40.00%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Low Promoter Commitment (0.03%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Omkar Pharmachem Financial Statements
Comprehensive financial data for Omkar Pharmachem including income statement, balance sheet and cash flow
About 532167 (Omkar Pharmachem)
Omkar Pharmachem (532167) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Chemicals & Petrochemicals sector with a current market capitalisation of ₹27.06 (Cr). Omkar Pharmachem has delivered a Return on Equity (ROE) of 2.14% and a ROCE of 3.04%. The debt-to-equity ratio stands at 0.01, reflecting the company's capital structure. Investors tracking 532167 share price can monitor key metrics including P/E ratio, promoter holding of 0.03%, and quarterly earnings growth.
Company Details
532167 Share Price: Frequently Asked Questions
What is the current share price of Omkar Pharmachem (532167)?
As of 30 Sept 2025, 03:25 pm IST, Omkar Pharmachem share price is ₹26.83. The 532167 stock has a market capitalisation of ₹27.06 (Cr) on NSE/BSE.
Is 532167 share price Overvalued or Undervalued?
532167 share price is currently trading at a P/E ratio of 150.33x, compared to the industry average of 22.17x. Based on this relative valuation, the Omkar Pharmachem stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of 532167 share price?
The 52-week high of 532167 share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Omkar Pharmachem share price?
Key factors influencing 532167 share price include quarterly earnings growth (Sales Growth: 0.00%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Omkar Pharmachem a good stock for long-term investment?
Omkar Pharmachem shows a 5-year Profit Growth of 22.59% and an ROE of 2.14%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.01 before investing in 532167 shares.
How does Omkar Pharmachem compare with its industry peers?
Omkar Pharmachem competes with major peers in the Chemicals & Petrochemicals. Investors should compare 532167 share price P/E of 150.33x and ROE of 2.14% against the industry averages to determine competitive standing.
What is the P/E ratio of 532167 and what does it mean?
532167 share price has a P/E ratio of 150.33x compared to the industry average of 22.17x. Investors pay ₹150 for every ₹1 of annual earnings.
How is 532167 performing according to Bull Run's analysis?
532167 has a Bull Run fundamental score of 29/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does 532167 belong to?
532167 operates in the Chemicals & Petrochemicals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Omkar Pharmachem share price.
What is Return on Equity (ROE) and why is it important for 532167?
532167 has an ROE of 2.14%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Omkar Pharmachem generates profits from shareholders capital.
How is 532167 debt-to-equity ratio and what does it indicate?
532167 has a debt-to-equity ratio of 0.01, which indicates conservative financing with low financial risk.
What is 532167 dividend yield and is it a good dividend stock?
532167 offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Omkar Pharmachem shares.
How has 532167 share price grown over the past 5 years?
532167 has achieved 5-year growth rates of: Sales Growth 60.95%, Profit Growth 22.59%, and EPS Growth 22.59%.
What is the promoter holding in 532167 and why does it matter?
Promoters hold 0.03% of 532167 shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Omkar Pharmachem.
What is 532167 market capitalisation category?
532167 has a market capitalisation of ₹27 crores, placing it in the Small-cap category.
How volatile is 532167 stock?
532167 has a beta of N/A. A beta > 1 suggests the Omkar Pharmachem stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is 532167 operating profit margin trend?
532167 has a 5-year average Operating Profit Margin (OPM) of 49.79%, indicating the company's operational efficiency.
How is 532167 quarterly performance?
Recent quarterly performance shows Omkar Pharmachem YoY Sales Growth of 0.00% and YoY Profit Growth of -40.00%.
What is the institutional holding pattern in 532167?
532167 has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Omkar Pharmachem stock.